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OBJECTIVE — The purpose of this study was to examine trends in postpartum glucose
screeningforwomenwithgestationaldiabetesmellitus(GDM),predictorsofscreening,trendsin
postpartumimpairedfastingglucose(IFG)anddiabetes,anddiabetesandpre-diabetesdetected
by postpartum fasting plasma glucose (FPG) versus a 75-g oral glucose tolerance test (OGTT).
RESEARCH DESIGN AND METHODS — This was a cohort study of 14,448 GDM
pregnancies delivered between 1995 and 2006. Postpartum screening was deﬁned as perfor-
mance of either an FPG or OGTT at least 6 weeks after delivery and within 1 year of delivery.
RESULTS — Between 1995 and 2006, the age- and race/ethnicity-adjusted proportion of
women who were screened postpartum rose from 20.7% (95% CI 17.8–23.5) to 53.8% (51.3–
56.3). Older age, Asian or Hispanic race/ethnicity, higher education, earlier GDM diagnosis, use
of diabetes medications during pregnancy, and more provider contacts after delivery were
independent predictors of postpartum screening. Obesity and higher parity were independently
associated with lower screening performance. Among women who had postpartum screening,
the age- and race/ethnicity-adjusted proportion of IFG did not change over time (24.2 [95% CI
20.0–27.8] in 1995–1997 to 24.3 [22.6–26.0] in 2004–2006), but the proportion of women
with diabetes decreased from 6.1 (95% CI 4.2–8.1) in 1995–1997 to 3.3 (2.6–4.0) in 2004–
2006. Among women who received an OGTT in 2006, 38% of the 204 women with either
diabetes or pre-diabetes were identiﬁed only by the 2-h glucose measurements.
CONCLUSIONS — Postpartum screening has increased over the last decade, but it is still
suboptimal. Compared with FPGs alone, the 2-h values identify a higher proportion of women
with diabetes or pre-diabetes amenable to intervention.
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G
estational diabetes mellitus (GDM)
is deﬁned as carbohydrate intoler-
ance with onset of or ﬁrst recogni-
tion during pregnancy. Postpartum
diabetes screening may detect diabetes
that preceded pregnancy and therefore
enable early treatment of hyperglycemia,
reducing the risk of adverse fetal out-
comes in subsequent pregnancies (1) and
maternal microvascular complications
(2). Screening can also identify women
who might beneﬁt from diabetes preven-
tion interventions (3,4).
Performance rates of postpartum dia-
betes screening have been low (5–7), but
screeningperformancemayhavechanged
recently.Atpresent,onlyonepopulation-
based report has examined postpartum
diabetes screening practices, and this re-
port examined fasting plasma glucose
(FPG)only(8).WeuseddatafromaGDM
registry in a large prepaid group practice
managed health care organization (the
KaiserPermanenteMedicalCareProgram
in Northern California [KPNC]) and ex-
amined 1) postpartum diabetes screening
over time, 2) predictors of postpartum
screening in a detailed electronic medical
record, 3) trends in impaired fasting glu-
cose(IFG)ordiabetesdetectedwithpost-
partum screening, and 4) the proportion
of women with diabetes or pre-diabetes
identiﬁed by the FPG screen versus the
proportion of women with these abnor-
mal glucose values identiﬁed by the 75-g
oral glucose tolerance test (OGTT).
RESEARCH DESIGN AND
METHODS— This study was devel-
oped and approved by the Steering Com-
mittee of the Translating Research Into
Action for Diabetes (TRIAD) Study and
conducted in one of TRIAD’s six transla-
tional research centers, KPNC. KPNC is a
group practice, prepaid health plan that
provides comprehensive medical services
through 17 hospitals and 23 outpatient
clinics to 3 million members located in
a14-countyregioninNorthernCalifornia
(30% of the general population in the
geographic areas covered). The KPNC
membership closely approximates the
population living in the same geographic
area demographically except with respect
to income: KPNC members underrepre-
sent the very poor and the very wealthy
(9,10). Upon comparison with regional
birth certiﬁcates over a 14-year period,
there were no meaningful differences be-
tween women who delivered at a KPNC
hospital and women who delivered in the
underlying region regarding age at deliv-
ery or race, except that women who de-
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less likely to be Hispanic (25.8 vs.
32.0%).
We used the KPNC GDM registry
(11) to identify women with GDM who
deliveredbetween1January1995and31
December 2006. During this 12-year pe-
riod, the proportion of women who had
been screened for GDM with a 50-g, 1-h
oral challenge test during the second tri-
mester increased by 3% over time (age-
and race/ethnicity-adjusted proportions
92.5 [95% CI 92.3–92.7] in 1995–1997
vs. 95.7 [95.6–95.9] in 2004–2006). If
results were abnormal (1-h plasma glu-
cose levels 7.8 mmol/l [140 mg/dl]),
this test was followed by a standard diag-
nostic 100-g, 3-h OGTT. We identiﬁed
14,448 pregnancies that had a diagnosis
of GDM from a health provider and with
plasma glucose results during the index
pregnancy that met the National Diabetes
Data Group (NDDG) criteria on the 3-h
100-g OGTT for GDM, i.e., 2 glucose
values at or exceeding the following
thresholds: fasting, 105 mg/dl; 1 h, 190
mg/dl;2h,165mg/dl;and3h,145mg/dl
(12,13) without recognized preexisting
diabetes (14). We included only women
who met the NDDG criteria of GDM be-
cause, in this clinical setting, the NDDG
criteria were used for diagnosis of GDM
until January 2007. We also required that
these women had a diagnosis of GDM.
Approximately 550 women had no diag-
nosis of GDM but met the NDDG criteria
(equivalent to 4% of the size of our GDM
cohort with a diagnosis); women without
a diagnosis of GDM were excluded from
the analysis.
For the ﬁrst and second aims, the pri-
mary outcome was performance of post-
partumscreeningfordiabetesbyeitheran
FPG test alone or a 75-g, 2-h OGTT. Be-
cause several weeks may elapse before
glucose metabolism returns to normal in
most women with GDM (15), the Ameri-
can Diabetes Association (16) and the
American College of Obstetricians and
Gynecologists (17) both recommend that
postpartum glucose screening be per-
formed at 6 weeks postpartum or later.
We considered the postpartum screening
performed only if it was done during the
ﬁrst year after delivery starting from 6
weeksandifthewomanwasnotpregnant
again. For the third aim, the outcome was
the proportion of women identiﬁed with
either IFG (deﬁned as an FPG 100
mg/dl but 126 mg/dl) or diabetes diag-
nosed by FPG 126 mg/dl (18). Among
women who had postpartum screening,
the proportion receiving the OGTT
changed over time. Therefore, when we
report on trends in postpartum conver-
sion to diabetes, we report only on the
fasting values detected by either an FPG
or an OGTT. For the fourth aim, we ex-
amined the proportion of women who
were identiﬁed as having pre-diabetes on
the postpartum screen (that included IFG
as deﬁned above and impaired glucose
tolerance [IGT] deﬁned as a 2-h plasma
glucose value 140 mg/dl) or diabetes
(deﬁned as an FPG 126 mg/dl or a 2-h
plasma glucose value 200 mg/dl) (18).
Age, gestational age at delivery, race/
ethnicity, maternal body weight during
thebeginningofthesecondtrimester,and
gestationalageatGDMdiagnosiswereas-
certained from the computerized medical
records at birth. Use of insulin or gly-
buride during pregnancy was obtained
from the pharmacy database. Because we
had data on body weight but not on
height, a woman was considered obese if
her weight was 90th percentile of the
weight distribution of women of her race/
ethnicity in this study population. Infant
birth weight was obtained from the elec-
tronic medical record. Macrosomia was
deﬁnedasbirthweight4,000g.Dataon
annual household income were based on
census block data. Education and parity
were obtained by linkage with the state of
California birth certiﬁcate database. Be-
cause the lag time before state birth cer-
tiﬁcates became available is 3 years, we
have these variables for women who de-
livered between 1995 and 2004.
Statistical analysis
The yearly age- and race/ethnicity-
adjustedproportionofwomenwithGDM
who had postpartum glucose screening
and95%CIswerecalculatedbythedirect
method, in which the age and race/
ethnicity distribution of the entire study
population was used as the standard.
Among women who had postpartum
screening, the direct method was used to
calculate the yearly age- and race/
ethnicity-adjustedratesofIFGanddiabe-
tes diagnosed by FPG.
Predictors of postpartum screening
were examined in a multivariable logistic
regression model adjusted for age, race/
ethnicity, education, income, obesity,
parity, gestational age at GDM diagnosis,
glyburide and insulin use during preg-
nancy, a macrosomic infant at the index
pregnancy, visits to an internal medicine
or obstetrics/gynecology provider during
the postpartum period, year of delivery,
and medical facilities. SAS (version 9.1;
SAS Institute, Cary, NC) was used for all
analyses. This study was approved by the
human subjects committee of the Kaiser
Foundation Research Institute.
RESULTS
Trends in postpartum screening with
FPG performed alone or with an
OGTT
We identiﬁed 14,448 pregnancies com-
plicated by GDM occurring between
1995 and 2006 among KPNC members
whowereaged15–44yearsanddelivered
live infants or had still births. These preg-
nancies occurred among 13,547 women,
because 901 had more than one preg-
nancy during the 12-year study period.
The mean  SD age of women with GDM
was 32.3  5.4 years. The percentage of
women with GDM pregnancies who re-
Figure 1—Age- and race/ethnicity-adjusted proportions of postpartum screening for diabetes
among women with histories of GDM by year of delivery. The KPNC GDM registry: 1995–2006.
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testincreasedfrom1995(20.3%)to2006
(55.9%).
Between 1995 and 2006, the age of
women with GDM increased slightly
(28.2  5.7 to 28.8  6.0 years) and the
proportion of women with GDM who
were Hispanic increased markedly. The
race/ethnicity distributions in 1995 ver-
sus2006wereasfollows:60.7and43.4%
white, 14.5 and 15.4% Asian, 14.1 and
24.9% Hispanic, 6.7 and 6.7% African
American, 2.0 and 4.4% other, and 2.0
and 5.2% unknown. Changes in the de-
mographics represent changes in the en-
tire population with GDM, regardless of
performance of diagnostic screening. Af-
ter adjustment for age and race/ethnicity,
the proportion of women with GDM who
received a postpartum glucose screening
increased steadily over time from 20.7%
(95% CI 17.8–23.5) in women who de-
livered in 1995 to 53.8 (51.3–56.3) in
women who delivered in 2006 (Fig. 1).
Predictors in postpartum screening
Unadjusted characteristics of women by
postpartum screening status are illus-
trated in Table 1. In a multiple-adjusted
logistic regression model (Table 2), older
age, Asian or Hispanic race/ethnicity,
highereducation,atleasttwopriorbirths,
earlier gestational age at GDM diagnosis,
use of insulin or glyburide during preg-
nancy, and visits to an internal medicine
or obstetrics/gynecology provider during
the postpartum period were independent
and signiﬁcant predictors of postpartum
screening.Obesityandhigherparitywere
signiﬁcantly associated with less frequent
screening.
Trends in postpartum IFG and
diabetes
On the basis of FPG (either performed
alone or as part of the OGTT), 3.5% (n 
191)haddiabetesand22.0%(n1,228)
had IFG. The proportion of women with
IFG postpartum remained similar over
time, but the proportion of women with
diabetes decreased from 1995–1997 to
1998–2000 and then leveled off (Fig. 2).
Among women who delivered in 1995–
1997, 564 were screened at postpartum,
and 131 had IFG and 32 had diabetes by
FPG (age- and race/ethnicity-adjusted
rates 24.2 [95% CI 20.–27.8] and 6.1
[4.2–8.1], respectively). Among women
who delivered in 2004–2006, 2,381
women were screened, and 583 had IFG
and 80 had diabetes by FPG (age- and
Table 1—Characteristics of women with a history of GDM by postpartum glucose screening
status: KPNC GDM registry: 1995–2006
Without postpartum
glucose screening
With postpartum
glucose screening P
n 8,924 5,524
Age (years) 0.0001
25 9.4 5.4
25–35 64.1 63.0
36 26.6 31.6
Race/ethnicity 0.0001
Non-Hispanic white 34.8 28.0
African American 5.6 3.2
Asian 23.2 31.3
Hispanic 24.6 27.1
Other 4.8 5.6
Unknown 7.0 4.8
Education 0.0001
Less than high school 12.2 11.7
High school graduate 29.9 24.4
2-year college 23.4 20.9
4-year college 21.5 26.4
Postgraduate degree 11.3 15.2
Unknown 1.8 1.5
Annual household income 0.0003
$30,000 6.6 4.4
$30,000–59,000 43.3 38.0
$60,000–99,000 39.8 44.5
$100,000 4.9 6.8
Unknown 5.4 6.3
Parity 0.0003
0 37.4 40.4
1 32.5 32.8
2 30.1 26.8
Obese 10.4 8.9 0.0001
Gestational age at GDM diagnosis (weeks) 0.0001
20 8.4 13.7
20–24 3.9 4.8
25–30 57.2 63.9
31–37 26.4 14.0
38 0.7 0.2
Unknown 3.5 3.4
Plasma glucose at the 100-g OGTT
Fasting 0.29
95 mg/dl 58.0 58.0
95 but 105 mg/dl 20.3 21.2
105 mg/dl 21.7 20.9
1-h 0.16
180 mg/dl 10.5 9.6
180 but 190 mg/dl 5.9 5.7
190 mg/dl 83.5 84.6
2-h 0.85
155 mg/dl 5.5 5.4
155 but 165 mg/dl 3.3 3.2
165 mg/dl 91.1 91.4
3-h 0.99
140 mg/dl 46.7 46.7
140 but 145 mg/dl 4.4 4.4
145 mg/dl 49.0 49.0
Diabetes medication during pregnancy
Insulin 12.6 15.2 0.0001
Glyburide 6.4 13.9 0.0001
Macrosomic infant delivered 15.5 13.8 0.014
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26.0] and 3.3 [2.6–4.0], respectively).
Proportion of women with diabetes
and pre-diabetes on the basis of FPG
alone versus OGTT
The proportion of women receiving an
OGTT increased from 1995 (5.0%) to
2005 (16.6%) and markedly increased in
2006 (71.5%). In 2006, KPNC instituted
a nurse managed care program that in-
cluded greater attention to postpartum
screening guidelines. Among the 600
women who underwent a 75-g OGTT in
2006, 16 had diabetes at postpartum. Di-
abetes was diagnosed in 4 (25%) by FPG
alone. Of the remaining 12 women, 8
(50%) had IFG and 4 (25%) had normal
FPG. Of the 188 women who were found
to have pre-diabetes (i.e., either IFG or
IGT according to the fasting or 2-h glu-
cose values measured during the 75-g
OGTT), only 114 (60%) were diagnosed
withIFG;74(40%)wouldhavebeenclas-
siﬁed as having normal glucose tolerance
on the basis of FPG alone. Therefore, 78
(38%) of the 204 women with either dia-
betes or pre-diabetes were identiﬁed only
by the 2-h glucose measurements.
CONCLUSIONS — In a managed
care plan with a large number of women
withGDMpregnancies,wefoundthatbe-
tween1995and2006,screeningforpost-
partum diabetes increased from 20.7 to
53.8%. The increase in screening perfor-
manceisnotlikelytobeduetoadvancing
maternal age or changes in the racial/
ethniccompositionofwomenwithGDM,
as this trend in screening performance
was similar after adjustment for age and
race/ethnicity, and almost the entire pop-
ulation of pregnant women was screened
for GDM between 1995 and 2006. Al-
though the proportion of women with
IFG on their postpartum screen did not
signiﬁcantly change over time, the pro-
portion of women with diabetes (diag-
nosed by FPG levels) at postpartum
decreased by 50%. This observed de-
crease in diabetes among women with
postpartum screening is not likely to be a
consequence of the small increase (3%)
in GDM screening over time. The de-
crease is more likely because of better
identiﬁcation of diabetes before preg-
nancy, as suggested by the reported in-
crease in postpartum screening among
women with GDM and because of an
increase in glucose screening in post-
partum women without GDM (1.9% in
1995 vs. 8.2% in 2006).
As in other reports (5–8), the major-
ity of women in our cohort did not un-
dergo postpartum diabetes screening in
the early years of the study. Asian and
Hispanic women were more likely to un-
dergopostpartumscreening.Itispossible
that health care providers might have rec-
ommended more postpartum screening
among these racial/ethnic groups, given
theirhigherprevalenceofdiabetes(19).It
is also possible that Asian women were
more likely to have had a recent physical
examination, giving the health care pro-
vider the opportunity to recommend
screening, as suggested by racial/ethnic
differences in access to care among GDM
women (20). Similar to other reports, we
found that greater contact with medical
care, either through a postpartum visit or
other contacts, was associated with
greater postpartum screening and may
haveprovidedadditionalopportunitiesto
perform screening (6,7). Women who
were more likely to be screened also were
Table2—Multipleadjustedlogisticregressionmodelpredictingpostpartumglucosescreening
among women with history of GDM: the KPNC GDM registry: 1995–2006
Odds ratio (95% CI)
Age (years)
25 1.00
25–35 1.43 (1.23–1.67)
36 1.80 (1.52–2.14)
Race
Non-Hispanic white 1.00
African American 0.86 (0.70–1.05)
Asian 1.36 (1.23–1.51)
Hispanic 1.37 (1.23–1.52)
Other/missing 1.10 (0.96–1.27)
Education
Less than high school 1.02 (0.87–1.19)
High school graduate 1.00
2-year college 1.03 (0.91–1.17)
4-year college 1.22 (1.08–1.38)
Postgraduate education 1.21 (1.04–1.40)
Parity
0 1.00
1 0.93 (0.84–1.03)
2 0.82 (0.74–0.92)
Income
$30,000 1.00
$30,000–59,000 1.04 (0.87–1.24)
$60,000–99,000 1.07 (0.89–1.28)
$100,000 1.24 (0.98–1.57)
Obese
No 1.00
Yes 0.73 (0.63–0.86)
Gestational age at diagnosis of GDM (weeks)
20 1.00
20–24 0.89 (0.72–1.09)
25–30 0.90 (0.79–1.02)
31–37 0.55 (0.47–0.63)
38 0.30 (0.14–0.62)
Insulin use during pregnancy 1.51 (1.35–1.69)
Glyburide use during pregnancy 1.27 (1.12–1.45)
Macrosomic infant delivered
No 1.00
Yes 1.01 (0.90–1.12)
Postpartum visits
0 visits 1.00
1 visit 2.48 (1.95–3.16)
2 visits 4.85 (3.86–6.10)
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ment. Although reasons are speculative,
thesewomenmayhavehadgreateraware-
ness of their diabetes risk and the recom-
mendation for screening. In women who
were screened postpartum, GDM was di-
agnosed earlier in their index pregnancy,
and they were more likely to have been
treated with medications, which may
have increased their and their provider’s
awareness of their diabetes risk. Glucose
levelsonthediagnostic3-hOGTTduring
pregnancy were similar in women who
were and were not screened, suggesting
that these were not used to guide testing.
As shown by others (21), there was a sug-
gestion that some of the women with a
history of GDM who might have had a
higher risk of developing diabetes during
thepostpartumperiod,suchasthosewho
were obese or with higher parity, were less
likely to perform postpartum screening.
The American Diabetes Association
(16), the American College of Obstetri-
cians and Gynecologists (17), and the
Fifth International Congress Workshop
for Gestational Diabetes (15) endorse the
postpartum OGTT and FPG to different
extents.IfonlyFPGwereusedinpostpar-
tumscreening,74(40%)casesofIGTand
16 (75%) cases of diabetes would have
been missed. Kitzmiller et al. (19) re-
ported that among 527 women with
GDM, at postpartum 16.5% had isolated
IGT, only 16% of women in whom diabe-
teswasdiagnosedmetthecriteriaforboth
elevatedFPGand2-hvalues,and21of25
women met the criteria for diabetes ac-
cording to their 2-h values alone. Hunt
and Conway (21) also reported that one-
third of their postpartum GDM cohort
undergoing the OGTT and who had dia-
betes or pre-diabetes had isolated 2-h el-
evations. Their results are very similar to
those found in this study: 78 of 204
womencomparedwith41of117(or38%
vs. 35%). Therefore, the greater conve-
nience of the FPG needs to be weighed
carefully against its decreased sensitivity,
particularly among women with a history
of GDM.
This report has several limitations.
We were not able to distinguish whether
the lack of screening occurred because of
a lack of provider order or other reasons.
Such a distinction might have implica-
tions for interventions to improve screen-
ing performance. However, provider
orders for screening might occur only af-
ternegotiationwiththepatient,andalack
of provider order may, at least in part,
reﬂect women’s objections to the test. We
deﬁned obesity by using race/ethnicity-
speciﬁcpercentiles,ratherthanheight-to-
weight ratios, thus introducing the
possibility for misclassiﬁcation and artiﬁ-
cially decreasing the association between
obesity and screening to the null. Infor-
mation on other confounders, such as
family history of diabetes, was not avail-
able from electronic records.
Because the population of women
withGDMisofreproductiveage,postpar-
tum screening and subsequent diagnoses
ofdiabetesaffectnotonlythemothersbut
also future pregnancies. The risk of com-
plications, particularly stillbirths and
congenitalabnormalities,maybereduced
with optimal glycemic control before the
subsequent pregnancy (1). Prepregnancy
glycemic control might also reduce the
risk of the infant to the in utero exposure
tohyperglycemiathatmightleadtochild-
hoodobesityanddiabetes(22).Adiagno-
sis of pre-diabetes would identify women
at high risk of future maternal diabetes,
butthisriskcouldbereducedthroughthe
application of interventions such as thia-
zolidinediones, metformin, or intensive
lifestyle modiﬁcation (3,4).
We conclude that, among women
with a GDM history, postpartum diabetes
screening has increased, but screening is
still suboptimal. Performance of an FPG
alone, as opposed to the OGTT, will miss
a subpopulation of women at risk. Inter-
ventionsthatincreasepostpartumscreen-
ing performance are needed.
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